Echo Therapeutics to Present at the Jefferies Global Healthcare Conference

  Echo Therapeutics to Present at the Jefferies Global Healthcare Conference

PR Newswire

PHILADELPHIA, May 30, 2013

PHILADELPHIA, May 30, 2013 /PRNewswire/ --Echo Therapeutics, Inc. (Nasdaq:
ECTE), a company developing its needle-free Symphony^® CGM System as a
non-invasive, wireless, transdermal continuous glucose monitoring system,
today announced that Patrick T. Mooney, M.D., Chairman and CEO of Echo
Therapeutics will present at the Jefferies 2013 Global Healthcare Conference.

(Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO)

Dr. Mooney will make a presentation to prospective corporate partners and
investors at 2:00 PM EST on Thursday, June 6^th in New York City.

At the time of the presentation, a live webcast of Dr. Mooney's presentation
will be accessible in the Events section of the company's website at
www.echotx.com. A replay of the webcast will be available on the Company's
website for 30 days following the presentation. To ensure a timely
connection, it is recommended that users register at least 10 minutes prior to
the scheduled event.

About Echo Therapeutics


Echo Therapeutics is developing the Symphony CGM System as a non-invasive,
wireless, continuous glucose monitoring system. Our target is patients who
could benefit from glucose monitoring in the hospital setting, including
critical care. Significant opportunity also exists for patients with diabetes
to use Symphony in the outpatient setting. Echo is also developing its
needle-free skin preparation component of Symphony, the Prelude^® SkinPrep
System, as a platform technology to enhance drug delivery of topical
pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may
constitute forward-looking statements that are based on current expectations
and are subject to risks and uncertainties that could cause actual future
results to differ materially from those expressed or implied by such
statements. Those risks and uncertainties include, but are not limited to,
risks related to regulatory approvals and the success of Echo's ongoing
studies, including the safety and efficacy of Echo's Symphony CGM System, the
failure of future development and preliminary marketing efforts related to
Echo's Symphony CGM System, Echo's ability to secure additional commercial
partnering arrangements, risks and uncertainties relating to Echo's and its
partners' ability to develop, market and sell the Symphony CGM System, the
availability of substantial additional equity or debt capital to support its
research, development and product commercialization activities, and the
success of its research, development, regulatory approval, marketing and
distribution plans and strategies, including those plans and strategies
related to its Symphony CGM System. These and other risks and uncertainties
are identified and described in more detail in Echo's filings with the
Securities and Exchange Commission, including, without limitation, its Annual
Report on Form 10-K for the year ended December 31, 2012, its Quarterly
Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no
obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215)
717-4104

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx

SOURCE Echo Therapeutics, Inc.

Website: http://www.echotx.com
 
Press spacebar to pause and continue. Press esc to stop.